[ad_1]
Gilead Sciences Inc. on Thursday minimize 1 of its gain forecasts and described 1st-quarter revenue that missed anticipations, with weaker demand from customers for its COVID-19 drug weighing on outcomes.
The organization documented to start with-quarter internet earnings of $985 million, or 80 cents a share, in contrast with $12 million, or two cents a share, in the same quarter past calendar year. Earnings fell 4% to $6.35 billion, as opposed with $6.59 billion in the prior-year quarter.
Adjusted…
[ad_2]
Supply link